Cytek Biosciences Inc CTKB.OQ CTKB.O is expected to show a fall in quarterly revenue when it reports results on February 26 for the period ending December 31 2025
The Fremont California-based company is expected to report a 0.5% decrease in revenue to $57.187 million from $57.48 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.The company's guidance on January 12 2026, for the period ended December 31, was for revenue of $62.000 million.
LSEG's mean analyst estimate for Cytek Biosciences Inc is for a loss of 4 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Cytek Biosciences Inc is $6.00, about 36.7% above its last closing price of $4.39
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.06 | -0.05 | -0.04 | Beat | 23.8 |
Jun. 30 2025 | -0.08 | -0.07 | -0.04 | Beat | 42.9 |
Mar. 31 2025 | -0.04 | -0.04 | -0.09 | Missed | -100 |
Dec. 31 2024 | 0.05 | 0.05 | 0.07 | Beat | 34.6 |
Sep. 30 2024 | -0.02 | -0.01 | 0.01 | Beat | 166.7 |
Jun. 30 2024 | -0.03 | -0.03 | -0.08 | Missed | -166.7 |
Mar. 31 2024 | -0.04 | -0.04 | -0.05 | Missed | -25 |
Dec. 31 2023 | -0.01 | 0.00 | 0.04 | Beat | 1,101.2 |
This summary was machine generated February 24 at 21:51 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)